Proprietary AI analyst is now available

Taysha GTx Valuation Multiples

Discover revenue and EBITDA valuation multiples for Taysha GTx and similar public comparables like Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical and more.

Taysha GTx Overview

About Taysha GTx

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.


Founded

2019

HQ

United States

Employees

73

Financials (LTM)

Revenue: $6M
EBITDA: ($140M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Taysha GTx Financials

Taysha GTx reported last 12-month revenue of $6M and negative EBITDA of ($140M).

In the same LTM period, Taysha GTx generated $6M in gross profit, ($140M) in EBITDA losses, and had net loss of ($139M).

Revenue (LTM)


Taysha GTx P&L

In the most recent fiscal year, Taysha GTx reported revenue of $10M and EBITDA of ($108M).

Taysha GTx is unprofitable as of last fiscal year, with EBITDA margin of (1103%) and net margin of (1115%).

See analyst estimates for Taysha GTx
LTMLast FY202320242025202620272028
Revenue$6M$10M$15M$8M$10M
Gross Profit$6M---$10M
Gross Margin100%---100%
EBITDA($140M)($108M)($105M)($88M)($108M)
EBITDA Margin(2283%)(1103%)(681%)(1055%)(1103%)
EBIT Margin(2306%)(1130%)(462%)(1039%)(1131%)
Net Profit($139M)($109M)($112M)($89M)($109M)
Net Margin(2256%)(1115%)(722%)(1072%)(1115%)

Financial data powered by Morningstar, Inc.

Taysha GTx Stock Performance

Taysha GTx has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Taysha GTx's stock price is $6.42.

Taysha GTx share price increased by 9.6% in the last 30 days, and by 189.8% in the last year.

Taysha GTx has an EPS (earnings per share) of $-0.38.

See more trading valuation data for Taysha GTx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B3.7%9.6%43.6%189.8%$-0.38

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Taysha GTx Valuation Multiples

Taysha GTx trades at 266.0x EV/Revenue multiple, and (11.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Taysha GTx

EV / Revenue (LTM)


Taysha GTx Financial Valuation Multiples

As of June 19, 2026, Taysha GTx has market cap of $2B and EV of $2B.

Taysha GTx has a P/E ratio of (13.3x).

LTMLast FY202320242025202620272028
EV/Revenuen/m167.5x105.9x196.4x167.5x
EV/EBITDA(11.7x)(15.2x)(15.6x)(18.6x)(15.2x)
EV/EBIT(11.5x)(14.8x)(22.9x)(18.9x)(14.8x)
EV/Gross Profitn/m---167.5x
P/E(13.3x)(16.9x)(16.5x)(20.7x)(16.9x)
EV/FCF-(17.4x)(20.4x)(20.1x)(17.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Taysha GTx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Taysha GTx Margins & Growth Rates

Taysha GTx decreased revenue by 80% but EBITDA grew by 63% in the last fiscal year.

In the most recent fiscal year, Taysha GTx reported EBITDA margin of (1103%) and net margin of (1115%).

See estimated margins and future growth rates for Taysha GTx

Taysha GTx Margins

Last FY202420252026202720282029
Gross Margin--100%100%
EBITDA Margin(1103%)(1055%)(1103%)(8776%)
EBIT Margin(1130%)(1039%)(1131%)(8895%)
Net Margin(1115%)(1072%)(1115%)(8650%)
FCF Margin(960%)(979%)(960%)-

Taysha GTx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(80%)(46%)17%(80%)
Gross Profit Growth---(80%)
EBITDA Growth63%(16%)23%63%
EBIT Growth61%21%28%61%
Net Profit Growth59%(20%)22%59%
FCF Growth-2%15%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Taysha GTx Operational KPIs

Taysha GTx's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.6M for the same period.

Taysha GTx's Rule of 40 is (8856%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Taysha GTx's Rule of X is (8975%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Taysha GTx
LTMLast FY202320242025202620272028
Rule of 40(2088%)(8856%)---
Bessemer Rule of X(1795%)(8975%)---
Revenue per Employee-$0.1M---
Opex per Employee-$1.6M---
G&A Expenses to Revenue602%347%194%347%347%
R&D Expenses to Revenue1769%884%367%792%884%
Opex to Revenue-1231%562%1139%1231%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Taysha GTx Competitors

Taysha GTx competitors include Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical, Hanall Biopharma, Idorsia, Mesoblast, Galapagos, Nurix Therapeutics and HUTCHMED (China).

Most Taysha GTx public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Generate Biomedicines43.8x44.3x(6.7x)(5.9x)
Sarepta Therapeutics1.0x1.1x(3.8x)(40.8x)
Viridian Therapeutics17.7x21.2x(3.8x)(3.4x)
Jafron Biomedical5.5x5.4x12.0x11.7x
Hanall Biopharma17.3x17.0x531.8x479.7x
Idorsia12.1x12.1x(59.7x)(42.9x)
Mesoblast109.0x15.6x(27.3x)(72.0x)
Galapagos-(2.4x)-(17.4x)

This data is available for Pro users. Sign up to see all Taysha GTx competitors and their valuation data.

Start Free Trial

Taysha GTx VC Funding History

Before going public, Taysha GTx raised $125M in total equity funding, across 2 rounds.


Taysha GTx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-20Series BFidelity$95M-Taysha Gene Therapies is a Dallas-based biotechnology company founded in 2020, specializing in gene therapies for rare diseases, with 101-200 employees. It has raised $465 million across 4 funding rounds, including a $150M round in September 2023, $40M in January 2024, $75M in July 2024, and $200M in June 2025. The company went public via IPO raising $125M on September 24, 2020, trading on NASDAQ as TSHA with a current market cap around $1.3B and negative profitability metrics like -1,144.97% net margins and -$89.3M losses. Fidelity funds hold positions in Taysha Gene Therapies shares in recent portfolio reports.
Apr-20SeedNolan Capital; PBM Capital Group$30M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Taysha GTx

When was Taysha GTx founded?Taysha GTx was founded in 2019.
Where is Taysha GTx headquartered?Taysha GTx is headquartered in United States.
How many employees does Taysha GTx have?As of today, Taysha GTx has over 73 employees.
Who is the CEO of Taysha GTx?Taysha GTx's CEO is Sean P. Nolan.
Is Taysha GTx publicly listed?Yes, Taysha GTx is a public company listed on Nasdaq.
What is the stock symbol of Taysha GTx?Taysha GTx trades under TSHA ticker.
When did Taysha GTx go public?Taysha GTx went public in 2020.
Who are competitors of Taysha GTx?Taysha GTx main competitors include Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical, Hanall Biopharma, Idorsia, Mesoblast, Galapagos, Nurix Therapeutics, HUTCHMED (China).
What is the current market cap of Taysha GTx?Taysha GTx's current market cap is $2B.
What is the current revenue of Taysha GTx?Taysha GTx's last 12 months revenue is $6M.
What is the current revenue growth of Taysha GTx?Taysha GTx revenue growth (NTM/LTM) is 195%.
What is the current EV/Revenue multiple of Taysha GTx?Current revenue multiple of Taysha GTx is 266.0x.
Is Taysha GTx profitable?No, Taysha GTx is not profitable.
What is the current EBITDA of Taysha GTx?Taysha GTx has negative EBITDA and is not profitable.
What is Taysha GTx's EBITDA margin?Taysha GTx's last 12 months EBITDA margin is (2283%).
What is the current EV/EBITDA multiple of Taysha GTx?Current EBITDA multiple of Taysha GTx is (11.7x).
How many companies Taysha GTx has acquired to date?Taysha GTx hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Taysha GTx has invested to date?Taysha GTx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Taysha GTx

Lists including Taysha GTx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial